Retrophin (RTRX) : During the past 4 weeks, traders have been relatively bearish on Retrophin (RTRX), hence the stock is down -7.18% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -8.4% relative to the S&P 500. The 4-week change in the price of the stock is -6.22% and the stock has fallen -8.36% in the past 1 week.
The stock has recorded a 20-day Moving Average of 4.17% and the 50-Day Moving Average is 3.64%. Retrophin (NASDAQ:RTRX): On Fridays trading session , Opening price of the stock was $17.33 with an intraday high of $17.5. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $17.04. However, the stock managed to close at $17.33, a loss of 0.69% for the day. On the previous day, the stock had closed at $17.45. The total traded volume of the day was 508,629 shares.
The company Insiders own 2.41% of Retrophin shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -4.98% . During last six month period, the net percent change held by insiders has seen a change of -1.13%.
Retrophin, Inc. (Retrophin) is a biopharmaceutical company. The Company is focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and life-threatening diseases. The Company is focused on various catastrophic diseases affecting children, including focal segmental glomerulosclerosis (FSGS) and pantothenate kinase-associated neurodegeneration (PKAN). The Company is engaged in enrolling patients in a Phase II clinical trial for its lead compound, Sparsentan, for FSGS. The Companys products include Thiola (Tiopronin) and Chenodal. Its Thiola is used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Chenodal is a tablet of chenodiol (chenodeoxycholic acid). Its other products include RE-024 and RE-034, which are in pre-clinical stage.